Evidence map›Paper›PMID 27747578›Full record

ArticleRheumatology and therapy2016

Costs of Drug Therapy in Patients with Ankylosing Spondylitis in Brazil.

Marina Amaral de Ávila Machado, Felipe Ferre, Cristiano Soares de Moura, Alessandra Maciel Almeida, Eli Iola Gurgel Andrade, Mariângela Leal Cherchiglia, Francisco de Assis Acurcio

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Rheumatology and therapy, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed, 2 pooled it
0.3field-weighted citation impact, top 33% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 2 syntheses or guidelines pooled it, 7 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Article
  4. RUNX3 Polymorphisms Affect the Risk of Ankylosing Spondylitis.Medical science monitor : international medical journal of experimental and clinical research · 2020
    Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 3 institutions in 2 countries.

Marina Amaral de Ávila MachadoCollege of Medicine, Federal University of Minas Gerais, Av. Prof. Alfredo Balena 190, Belo Horizonte, 30130-100, MG, Brazil. avila110@yahoo.com.br.
Felipe FerreCollege of Medicine, Federal University of Minas Gerais, Av. Prof. Alfredo Balena 190, Belo Horizonte, 30130-100, MG, Brazil.
Cristiano Soares de MouraDivision of Clinical Epidemiology, McGill University, 687 Pine Avenue West, V-Pavilion, Montreal, QC, Canada.
Alessandra Maciel AlmeidaFaculty of Medical Sciences of Minas Gerais, Alameda Ezequiel Dias 275, Belo Horizonte, MG, Brazil.
Eli Iola Gurgel AndradeCollege of Medicine, Federal University of Minas Gerais, Av. Prof. Alfredo Balena 190, Belo Horizonte, 30130-100, MG, Brazil.
Mariângela Leal CherchigliaCollege of Medicine, Federal University of Minas Gerais, Av. Prof. Alfredo Balena 190, Belo Horizonte, 30130-100, MG, Brazil.
Francisco de Assis AcurcioSocial Pharmacy Department, College of Pharmacy, Federal University of Minas Gerais, Av. Presidente Antônio Carlos 6627, Belo Horizonte, MG, Brazil.
Universidade Federal de Minas Gerais · BRFaculdade de Ciências Médicas de Minas Gerais · BRMcGill University · CA

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionThe Brazilian Public Health System offers free-of-charge drug treatment for ankylosing spondylitis (AS) to all Brazilian citizens. We report here the first population-based cohort study on patients with AS in Brazil. The aim of this study was to evaluate the costs of the tumour necrosis factor (anti-TNF) blockers and disease-modifying antirheumatic drugs (DMARDs) that were used in the treatments of patients with AS in Brazil between March 2010 and September 2013.

methodsA retrospective cohort study was performed using administrative databases. All patients with a diagnosis of AS who were aged 18 years or older and had been dispensed anti-TNF or DMARDs were included in the analysis. The cost analysis was carried out from the health system perspective, and the results were described as median monthly cost per capita and the annual cost over the study period.

resultsA search of the databases identified 1251 patients with AS who were treated during the study period, of whom 63.3% were male; the median age was 41 years. During the study period, 78.0% of patients initiated treatment with anti-TNF drugs and 22.0% with DMARDs. The median monthly cost per capita was US$ 1650 for anti-TNF therapy and US$ 25 for treatment with DMARDs. Among the anti-TNF drugs, therapy with etanercept was associated with the lowest cost per patient, followed by adalimumab and infliximab. No difference in monthly cost was observed in relation to gender and age.

conclusionThe cost per patient of treating AS in this study cohort was lower with etanercept than with adalimumab and infliximab. These results highlights the economic burden of treating patients with AS.

Indexed as

Administrative claims dataAnkylosing spondylitisAnti-TNF therapyDMARDsDrug cost

Identifiers

PMID27747578
PMCPMC5127960
OpenAlexW2470479127

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.